Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc. possesses a promising portfolio of therapeutic candidates, including taletrectinib, which targets unmet needs in oncology, particularly in ROS1+ non-small cell lung cancer. The company's product candidates, including Safusidenib and NUV-868, exhibit high potency and improved tolerability potential, supported by clinical data that suggests strong efficacy, which could unlock significant market opportunities in competitive segments. With revenues generated through collaborative agreements in high-demand markets like China and Japan, Nuvation Bio's innovative drug-drug conjugate platform further positions it competitively within the biopharmaceutical landscape, allowing for enhanced therapeutic targeting and reduced toxicity.

Bears say

Nuvation Bio faces significant challenges, including an inability to advance key clinical assets, raising concerns about its strategic direction and long-term viability in the competitive oncology market. The company may encounter negative clinical proof-of-concept data for its pipeline programs, including taletrectinib, which could hinder commercial uptake and escalate the risk of long-term dilution for investors. Additionally, the potential difficulties in securing partnerships for the development and commercialization of its products could further delay or derail progress, exacerbating the company's financial uncertainties.

Nuvation Bio (NUVB) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Nuvation Bio (NUVB) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.